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When BALB/c mice were injected with a syngeneic cell line transformed by
Abelson murine leukemia virus (A-MuLV), the tumor was usually lethal. In sera
from tumor-bearing mice, and at highest levels in sera from mice that reject their
tumors, was an antibody that immunoprecipitates a specific protein from [35S]_
methionine-labeled A-MuLV-transformed BALB/c cells. This protein was not
the previously characterized A-MuLV-specific protein (P120) but a 50,000-molec-
ular-weight protein (P50). Such sera may also immunoprecipitate P120, but no
other protein was reproducibly prepipitated by them. A monoclonal antibody
(RA3-2C2) that has been shown to stain normal B-lymphocytes also selectively
immunoprecipitated P50. P50 was present in A-MuLV-transformed lymphoid and
fibroblastic cells of a variety of mouse strains. One A-MuLV-transformed cell line
had a very low P50 level, the L1-2 tumor of C57L origin. This tumor was
previously shown to be rejected by C57L mice and is used to produce anti-P120
(anti-AbT) sera. P50 was not a Moloney MuLV protein and was found at low
levels in normal cells or cells transformed by agents other than A-MuLV; thus, it
was probably a host cell protein whose concentration was selectively accentuated
by A-MuLV transformation. P50 was phosphorylated and, by using indirect
immunofluorescence, anti-P50 serum stained live A-MuLV-transformed cells. The
protein was not glycosylated and did not label by lactoperoxidase-catalyzed
iodination. Thus, P50 was very like P120 in its cellular localization and properties,
but it did not exhibit protein kinase activity in vitro. The selective accentuation
of this protein in A-MuLV transformants and its strong antigenicity in syngeneic
animals suggest that it is a unique and functionally important protein.
Abelson murine leukemia virus (A-MuLV)
can transform certain murine bone marrow cells
into continuous cell lines (18-20). When these
lines are injected into syngeneic mice, the cells
usually grow progressively and ultimately kill
their host (18). Only one cell line, the L1-2 line
from C57L mice, is reproducibly rejected by its
host, and after multiple challenges animals make
antisera that recognize the A-MuLV protein
(28). In the prototype A-MuLV strain, the viral
protein is called P120 and is the only known
product of the viral genome (15, 29). A-MuLV is
a defective virus and must be propagated with
a helper virus, usually Moloney MuLV (M-
MuLV); infected cells, therefore, often contain
the helper virus proteins Pr65Vg and Pr80env.
We have now found that sera taken from mice
with growing tumors occasionally contain anti-
bodies against another protein. This protein,
P50, is a cellular, not a viral, protein that is
peculiarly antigenic.
t Present address: Department of Microbiology and Molec-
ular Biology Institute, University of California, Los Angeles,
CA 90024.
MATERIALS AND METHODS
Mice. BALB/cN female mice between 8 and 12
weeks of age from our colony were used in the present
experiments.
Cell lines. The following A-MuLV-transformed cell
lines ofBALB/c origin were used: 2M3, a nonproducer;
2M3/M, a producer of A-MuLV and M-MuLV; 3-1, 1-
8, 18-48, 18-81, and FL-El (18, 23); 70Z, a BALB/c
chemically induced pre-B-lymphocyte line (13), Sp2/
0, a nonproducer variant of the P3/X63Ag8 myeloma
(7); and RLd1, a BALB/c radiation-induced T-cell
leukemia (21).
The following cell lines of C57L/J origin were used:
L1-2, an A-MuLV-transformed lymphoid cell line (28);
and L691, a radiation-induced leukemia (1).
The following cell lines of NIH/3T3 derivation were
used: ANN-1, A-MuLV-transformed nonproducer
(22); A2, A-MuLV-transformed nonproducer; and A2/
M, A2 superinfected with M-MuLV.
Lymphoid cell lines were grown in RPMI-1640 en-
riched with 10% heat-inactivated fetal calf serum and
2 x 10-5 M fl-mercaptoethanol. Fibroblastic cell lines
were grown in Dulbecco-modified Eagle medium en-
riched with 10% calf serum.
Immune sera. Anti-P50 antibodies were obtained
from BALB/c mice bearing syngeneic A-MuLV-in-
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duced tumors. Anti-P120 antibodies were obtained
from C57L/J mice that had rejected the syngeneic Ll-
2 A-MuLV-induced tumor cells and were further im-
munized with the same tumor cells (28). Goat anti-M-
MuLV virion protein antibodies were provided by the
Division of Cancer Cause and Prevention, National
Cancer Institute, Bethesda, Md. The RA3-2C2 mon-
oclonal anti-P50 antibody was obtained after fusion of
S194/Bu-1 mouse myeloma cells with spleen cells ob-
tained from rats hyperimmunized with the mouse cell
line RAW112, induced by infection of BALB/c mice
with A-MuLV (R. Coffman and I. Weissman, manu-
script in preparation). RA3-2C2 was chosen for study
because the antibodies showed surface binding to the
A-MuLV-induced tumor cells.
Cell labeling and immunoprecipitation. Radio-
active chemicals were purchased from New England
Nuclear Corp., Boston, Mass. Cells were washed sev-
eral times with phosphate-buffered saline and then
suspended in the labeling medium at a concentration
of 107 cells per ml. When labeled with [35S]methionine,
cells were resuspended in Dulbecco-modified Eagle
medium without methionine and enriched with 10%
dialyzed heat-inactivated fetal calf serum and 125 ,uCi
of [35S]methionine per ml. Cells were incubated for 1
h at 37°C. When labeled with [3H]leucine, 200 to 400
,uCi/ml was added to cells resuspended in Dulbecco-
modified Eagle medium without leucine and incubated
for 1 to 2 h at 37°C. When labeled with 32P04, the cells
were resuspended in Dulbecco-modified Eagle me-
dium without P04, 300 iCi of 32P04 per ml was added,
and the cells were incubated for 5 h at 37°C.
Cells were iodinated by two techniques. Lactoper-
oxidase-catalyzed iodination at room temperature was
performed by adding 500 [LCi of Na125I per 2 x 107 cells
with 50,g of lactoperoxidase (grade B, Calbiochem,
La Jolla, Calif.). Iodination by '251-labeled Bolton-
Hunter reagent was performed at 0°C. Cells (2 x 107)
were mixed with 75 uCi of '251-labeled Bolton-Hunter
reagent, suspended in phosphate-buffered saline, and
incubated for 1 h on ice. For both of these techniques,
cells were washed after labeling with phosphate-
buffered saline containing bovine serum albumin (1
mg/ml) to quench excess reagent.
Labeled cells were washed in phosphate-buffered
saline, and the pellet of cells was extracted into 5 ml
of lysis buffer (10 mM NaH2PO4-Na2HPO4, pH 7.5;
100 mM NaCl; 1% Triton X-100, 0.5% sodium deoxy-
cholate; 0.1% sodium dodecyl sulfate) at 0°C and clar-
ified at 150,000 x g for 2 to 3 h as previously described
(29). Fractions of 0.5 to 1 ml of cell lysate were im-
munoprecipitated with normal or immune serum. An-
tigen-antibody complexes were collected by binding to
Staphylococcus aureus (6). Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was performed on
the discontinuous stacking system of Laemmli (9).
Membrane immunofluorescence. All sera and
media employed were filtered through 0.2-,um filters.
Viable cells were washed several times in phosphate-
buffered saline with 10% heat-inactivated fetal calf
serum and finally resuspended to 0.5 x 106 cells per 50
pi, and 5 pl of normal or immune serum was added.
Cells were incubated for 30 min on ice, then washed
twice with cold phosphate-buffered saline with 10%
heat-inactivated fetal calf serum, and resuspended in
50 ,lI of pretitrated, fluorescein-conjugated second-
stage antibody. The second-stage antibody was goat
anti-mouse immunoglobulin G (Meloy Laboratories,
Springfield, Va.) when mouse sera were used and
rabbit anti-rat immunoglobulin G when the hybridoma
reagent was used.
Partial protease digestion. Partial protease
digestion was performed by the method of Cleveland
et al. (3). Certain batches of sera and RA3-2C2 im-
munoprecipitate a single protein band; for these cases
protein digestion was performed directly after immu-
noprecipitation of the proteins. S. aureus V-8 enzyme
was added to the immunoprecipitated protein and
incubated at 37°C for 1 h. The reaction was stopped
by adding 2x sample buffer and boiling for 2 min.
Samples were then analyzed by electrophoresis
through 10% polyacrylamide-sodium dodecyl sulfate
gels as described above.
RESULTS
Subcutaneous injection of 5 x 104 2M3/M
cells (an A-MuLV-transformed, producer cell
line) into syngeneic BALB/c mice produced a 95
to 100% tumor take within 10 to 12 days, which
was usually lethal within another 20 to 30 days.
Sera taken at a late stage of tumor development
from some of these mice could immunoprecipi-
tate a 50,000-molecular-weight protein (P50)
from lysates of [35S]methionine-labeled 2M3/M
cells (results with sera from 21 individual mice
are shown in Fig. 1). Because the P50 happens
to migrate at the leading edge of a large band of
mouse immunoglobulin, its migration rate often
seems slightly variable. By examining stained
gels, it is evident that the variability is a conse-
quence of varying amounts of immunoglobulin.
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FIG. 1. Detection of anti-P50 activity. BALBIc
mice were inoculated subcutaneously with 5 x 104
viable 2M3/M syngeneic A-MuL V-transformed
lymphoid cells, and individual serum samples ob-
tained from 21 mice were screened. Mice were kept in
groups offour to five. Serum was collected from tumor
bearers 3 weeks after tumor appearance. Portions of
5 ul were used to immunoprecipitate extracts of
[35Slmethionine-labeled 2M3/M cells. Normal serum
(N) of BALB/c mice was also tested. Precipitates
were collected on S. aureus and analyzed by electro-
phoresis through a 10%o polyacrylamide-sodium do-
decyl sulfate gel.
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pitated P120, producer cell lines (unpublished data). Thus, the
era collected P50 protein immunoprecipitated from A-MuLV-
development transformed cell lines does not appear to share
specific pro- immunological determinants with M-MuLV
tate P50 "TB proteins.
imor-bearing Presence of P50 protein in other A-
MuLV-transformed cell lines. To test
NV viral ge- whether P50 is generally present in A-MuLV-
O was a viral transformed cell lines, a variety of such lines was
ined the pos- examined. The first group of cell lines tested
an M-MuLV were BALB/c lymphoid cell lines induced by an
Extracts of in vitro infection of bone marrow cells with A-
cells were, MuLV. Most of these cell lines were previously
ng amount of characterized as pre-B-lymphocytes (14, 23, 24)
I-MuLV pro- and had been found to contain the P120 A-
The virion MuLV protein. Cell lines 18-48, 3-1, 1-8, 18-81,
on of P50 by FL-El, and 2M3/M contained the P50 protein,
but they did as demonstrated by immunoprecipitation with
I-MuLV-spe- TB sera (Table 1). Cell line 37-2, an A-MuLV-
id a 50K M- induced lymphoid cell line of C57BL/6 origin,
rough h) evi- also had P50 (Fig. 3). This cell line contains a
V and immu- P160 A-MuLV protein rather than the P120
[uLV sera. found in other lines; this is a consequence of the
r P50, lysates A-MuLV virus strain used to produce the cell
nsformed by line (N. Rosenberg, 0. Witte, and D. Baltimore,
ed with nor- Cold Spring Harbor Symp. Quant. Biol., in
goat anti-M- press). Another lymphoid cell line, L1-2 of C57L
,cipitated no origin (28), had either no detectable P50 when
recipitated a lysates of [35S]methionine-labeled cells were im-
e of P50, and munoprecipitated with two different batches of
ly P120 (Fig. TB sera or a very faint band (Fig. 3). P50 was
also undetectable when a [3H]leucine-labeledZM3 L1-2 cell lysate was immunoprecipitated with
k TB sera. The L1-2 cell line demonstrates a clear
band of P120 when it is immunoprecipitated
P120- @ with anti-AbT sera (the sera of C57L mice that
have rejected the L1-2 tumor [28]). Anti-AbT
sera were characterized previously as precipitat-
ing P120, but P50 was not detected. It appears
P50-- from the present result that the lack of anti-P50
FIG. 2. Lack of blocking ofP50 byM-MuLV virion
proteins. Extracts of[35S]methionine-labeled2M3/M
cells were immunoprecipitated with TB serum (lanes
a through d) or with goat sera reactive with M-MuLV
virion proteins (lanes e through h) in the presence of
the following concentrations ofM-MuLV virion pro-
teins: lanes a and e, 0; lanes b and f, 50 .g; lanes c
and g, 75 pg; and lanes d and h, 100 pg. Extracts of
[358]methionine-labeled 2M3 cells were also immu-
noprecipitated with (i) normal serum, (a) TB serum,
or (k) goat anti-M-MuLV virion protein serum.
TABLE 1. Presence ofP50 in BALB/c A-MuL V-
transformed lymphoid cell lines
Cell line Origin P120a P50a
2M3/M Bone marrow ++ +++
18-48 Bone marrow ++ ++
18-81 Bone marrow ++ ++
3-1 Bone marrow ++ ++
1-8 Bone marrow ++ ++
FL-El Fetal liver ++ +
a A band of P120 or P50 was evident in extracts of
cell lines and was estimated as: +++, equivalent to a
radioactive protein band of 3,000 cpm; ++, equivalent
to a radioactive band of 1,000 to 2,000 cpm; and +,
equivalent to a radioactive protein band of less than
1,000 cpm.
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in anti-AbT sera could be a conse- 3T3 fibroblasts, where at most a very faint band
he low amount of P50 on L1-2 cells. of P50 was present. After a 1-h pulse and chases
anti-AbT sera do precipitate P50, for 1, 2, and 4 h, P50 was present at a greatly
iat L1-2 may have some P50 (see increased concentration in ANN-1 cells com-
iether the reproducible rejection of pared with NIH/3T3 cells. Thus, both fibro-
s by C57L mice is a consequence of blastic and lymphoid A-MuLV-transformed cell
P50 on these cells is under investi- lines contain a P50 protein that is specifically
immunoprecipitated with TB sera.
group of cell lines tested for P50 were Detection of the P50 in non-A-MuLV-
ansformed fibroblasts of NIH/Swiss transformed cell lines and normal lymph-
sera immunoprecipitated a P50 pro- oid cells. The following group of cell lines, all
rsates of two [35S]methionine-labeled produced by means other than A-MuLV trans-
)r cell lines, ANN-1 (Fig. 3) and A2 formation, were examined for the presence of
-d data). The amount of P50 detected P50. They were: RL1, a radiation-induced T-
mnd A2 was significantly lower than cell leukemia of BALB/c origin (1); 70Z, a chem-
[uLV-induced lymphoid lines tested, ically induced pre-B lymphoid cell line (13);
ich higher than in uninfected NIH/ Sp2/0, a nonproducer variant of the mouse mye-
loma P3/X63Ag8 (7); and L-691, a radiation-
induced T-cell leukemia of C57L mice (1). All of
these lines gave rise to a very faint band of P50
- -, + that was detected on autoradiograms after a
very long exposure (Fig. 4). TB sera immuno-
--- *^ ^ precipitated a heavy band of P50 protein from
v 2M3 cells under the same experimental condi-
tions. A faint band of P50 was also detected in
9 *---6 * extracts of [35S]methionine-labeled normal tis-
sues (thymus, spleen, bone marrow, lymph
nodes, or fetal liver cells) immunoprecipitated
with TB sera. Figure 4 illustrates an example of
labeled BALB/c thymus cells; for this experi-
ment 10-fold more cells were used than for 2M3,
showing how much less P50 is present in normal
cells than in A-MuLV-transformed cells.
*esence of P50 in A-MuLV-transformed Tes tha tr theP efial
,ells and cells of different mouse strains. These results suggest that the P50 specifcaffy
were: ANN-I, fibroblastic cells of NIHI immunoprecipitated with TB sera is a host pro-
37-2, lymphoid cells of C57BL/6 origin- tein present at abnormally high concentrations
nphoid cells of C57L/J origin. Extracts in most cell lines transformed by A-MuLV, but
tated with (a) normal serum, (b) TB se- present at low levels in most other cell lines and
a separate TB serum. in normal lymphoid tissues.
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FIG. 4. Presence of P50 in cells transformed by means other than A-MuLV and in normal thymocytes.
Extracts of ['5S]methionine-labeled Sp2/0, 70Z, RL61, L-691, and 2M3 cells were immunoprecipitated with
(a) normal serum or (b) TB serum. Thymus cells (108) ofBALB/c mice were also labeled with ['5Slmethionine,
lysed, precleared with S. aureus, and immunoprecipitated with (a) normal serum or (b) TB serum.
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Characterization of P50. To test whether
P50 is a phosphoprotein, 2M3 cells were labeled
for 5 h with 32PO4, and a cell lysate was prepared.
TB serum immunoprecipitated a labeled 50,000-
molecular-weight protein from the lysate as well
as the A-MuLV P120 (Fig. 5, lane c). The P120
phosphorylated A-MuLV protein was also de-
tected when this cell lysate was immunoprecip-
itated with anti-AbT serum (lane b). No phos-
phoproteins could be detected when normal se-
rum was used (lane a). Labeling the same cells
with [3H]leucine and immunoprecipitation with
the same sera showed marker bands of P120 and
P50 (Fig. 5).
To determine whether determinants of P50
were expressed on the exterior surface of cells,
live 2M3 (A-MuLV-transformed, nonproducer)
cells were incubated on ice with TB or normal
serum and then reacted with a fluoresceinated
goat anti-mouse antiserum. Fluorescence was
detected on the cell surface as a ring of staining
(Fig. 6a). The TB serum used in this experiment
contained some anti-P120 activity that could
have contributed to the cell surface labeling.
Thus, we repeated the experiment with the mon-
oclonal anti-P50 antibody (RA3-2C2) described
below and again found staining. This reagent
also stained L1-2 cells, although weakly.
Because P50 appears to be a membrane pro-
tein, it was of interest to test whether it is also
a glycoprotein. To this end, a [35S]methionine-







FIG. 5. In vivo phosphorylation of P50. 2M3 cells
were labeled for 5 h with 32PO4, and a cell lysate was
immunoprecipitated with (a) normal serum, (b) anti-
AbT serum, and (c) TB serum. [3H]leucine-labeled
2M3 cells were also immunoprecipitated with the
same antibodies.
tated with TB or goat anti-M-MuLV serum and
then treated with endo-/8-acetylglucosaminidase
H, an enzyme that cleaves off the mannose-
containing carbohydrate structures from re-
cently made glycoproteins (26). If P50 were a
glycoprotein, such treatment should change its
electrophoretic mobility. No change, however,
was evident in the mobility of P50 after such
treatment (Fig. 7, lanes a and b). The experiment
was internally controlled by the increased mo-
bility of Pr8Oenv of M-MuLV after treatment
(Fig. 7, lanes a and b). Thus, although P50 is a
membrane protein, it is apparently not glycosyl-
ated. In its surface localization, phosphorylation,
and lack of glycosylation, P50 is like the A-
MuLV P120 (28).
Because P50 is expressed on the cell surface,
it seemed possible that it could be labeled by
lactoperoxidase-catalyzed iodination. When
2M3/M cells were labeled in this way, however,
the only iodinated protein that could be detected
was the viral gp7O (Fig. 7, lanes c and d). With
2M3 cells, labeling of P50 was also not detecta-
ble. P50 could be iodinated when 2M3/M cells
were labeled with Bolton-Hunter reagent (Fig.
7, lanes e and f). Under these conditions P120
and Pr80env were also iodinated. This reagent
penetrates into cells and reacts rapidly with free
amino acid groups.
Antisera that precipitate P50. The TB sera
used in the studies described above were not the
only sera that precipitated P50. Some (2 of 80)
BALB/c mice rejected the syngeneic A-MuLV-
induced tumor, 2M3/M, and became immune to
further challenge: their sera contained high ti-
ters of antibody that precipitated P50 from
2M3/M cells, but not L1-2 cells (Fig. 8, lanes c).
Also, certain anti-P120 antibody preparations
made in C57L mice (28) have anti-P50 activity.
More importantly, however, antibodies from
quite different sources also precipitated P50.
One highly active anti-P50 serum was the mon-
oclonal antibody RA3-2C2 derived by immuniz-
ing rats with murine A-MuLV-induced tumor
cells (Coffman and Weissman, in preparation).
This monoclonal antibody was shown to stain
all B-lymphocytes, but not thymocytes. The an-
tibody precipitated a 50,000-molecular-weight
protein from 2M3/M cells, but no detectable
protein from L1-2 cells (Fig. 8, lanes d).
To examine whether RA3-2C2 actually re-
acted with the same protein as did TB sera, the
P50 bands precipitated by the sera were ana-
lyzed by partial protease digestion and electro-
phoresis (Fig. 9). There was complete identity of
partial cleavage products (lanes b and d), and
the protein precipitated by serum from BALB/
c mice that had rejected tumors also gave the
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FIG. 6. Detection ofP50 protein as an A-MuLV cell surface antigen by immunofluorescence. Intact, viable
2M3 cells were tested in a two-stage immunofluorescence assay, using normal mouse or TB serum at a final
dilution of 1:20. After unbound antibody was washed away, fluoresceinated goat anti-mouse immunoglobulin
G at a 1:20 final dilution was used and wet mounts were photographed. (a) Cells treated with TB serum,
fluorescence; (b) cells treated with TB serum, phase contrast; (c) cells treated with normal serum, fluorescence;
and (d) cells treated with normal serum, phase contrast.
same pattern (lane f). Thus, these sera precipi-
tate indistinguishable proteins.
DISCUSSION
When A-MuLV-induced lymphoid tumor cells
are growing in mice, the animals frequently form
antibodies to one host-encoded protein, P50.
The protein can be found in small amounts in
normal lymphoid cells and non-A-MuLV-in-
duced tumors, but is found at greatly accen-
tuated levels in most A-MuLV-induced tumor
cells (and certain other tumor cell lines; V. Rot-
ter and D. Baltimore, unpublished data). Of all
the A-MuLV-induced lymphoid cell lines ex-
amined, only the L1-2 tumor of C57L origin was
lacking sufficient P50 to yield a dark band after
[35S]methionine labeling under a standard set of
conditions. Even fibroblastic cells transformed
by A-MuLV had a significant amount of P50.
Accumulation of P50 in A-MuLV-transformed
cells could be a result of either a stabilization of
a labile P50 protein found in normal tissues or
induction of increased production of this protein
in the A-MuLV-transformed cells.
The recognition of P50 by both TB sera and
the monoclonal antibody RA3-2C2 has been
used to study this protein. The immunofluores-
cence ofA-MuLV-induced tumor cells with both
TB sera and RA3-2C2 suggests that some P50
molecules are at least partly exposed on the
outer surface of cells. Also, the demonstration of
the RA3-2C2 determinant on the surface of nor-
mal B-lymphocytes (Coffman and Weissman, in
preparation) suggests that P50 is a normal cell
membrane protein. It is curious but perhaps
significant that RA3-2C2 does not label the sur-
face of thymocytes (Coffmnan and Weissman, in
preparation), but P50 is easily detected in bio-
synthetically labeled thymocytes by using RA3-
2C2 antibody.
Among the more remarkable properties ofP50
is its close similarity to the A-MuLV P120 pro-
tein. Although the two proteins share no known
immunological determinants (certain C57L anti-
P120 sera do not precipitate P50, and RA3-2C2
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FIG. 7. Iodination of P50 and resistance to endo-
f,-N-acetylglucosaminidase H (endo H) treatment.
[35S]methionine-labeled 2M3/M cells were immuno-
precipitated with TB serum and (a) left without en-
zyme or (b) treated with endo-,f-N-acetylglucosamin-
idase H. The digestion products were analyzed by
electrophoresis through apolyacrylamide-sodium do-
decyl sulfate gel. 2M3/M cells were labeled with
Na125I by the lactoperoxidase technique, and a cell
lysate was immunoprecipitated with (c) normal serum
or (d) TB serum. 2M3/M cells were labeled with the
"251-labeled Bolton-Hunter reagent, and cell lysates
were immunoprecipitated with (e) normal serum or
(t) TB serum.
2M3/M
a b c d
L12
a b c d
go Pr80ent_v
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FIG. 8. Immunoprecipitation of P50 protein with
antibodies obtained from various sources. Lysates of
[35S]methionine-labeled 2M3 cells and Ll-2 cells
were immunoprecipitated with: (lane a) normal se-
rum; (b) TB serum; (c) serum of a BALB/c mouse
that rejected a 2M3/M tumor; and (d) RA3-2C2
hybridoma antibody.
does not precipitate P120), they have similarities
in that: (i) they are both partly exposed on the
surface of cells; (ii) they are both phosphorylated
in cells; (iii) they both lack detectable aspara-
gine-linked carbohydrate of the type that is sen-
sitive to endo-,8-N-acetylglucosaminidase H; (iv)
neither protein can be labeled by lactoperoxi-
dase-catalyzed iodination of live cells; and (v)
* -P50-
FIG. 9. Comparison of partial digestion products
by S. aureus V-8 of P50 protein immunoprecipitated
by different antibodies. Extracts of [3S]methionine-
labeled 2M3 cells were immunoprecipitated with (a)
RA3-2C2 hybridoma antibodies, (c) TB serum, or (e)
serum from a BALB/c mouse that rejected a synge-
neic 2M3/M tumor. Peptide digestion was obtained
by treating the above proteins with 0.025 4g of S.
aureus V-8 for 30 min at 37°C. Partial digestion
products of P50 immunoprecipitated by (b) RA3-2C2
hybridoma antibodies, (d) TB serum, or (/) serum
from a BALB/c mouse that rejected a syngeneic 2M3/
M tumor were compared.
P50 and the normal cell equivalent of P120,
called NCP150, are both most readily demon-
strable in normal thymocytes. P50, however,
does not become phosphorylated by incubation
with [y-32P]ATP in an immunoprecipitate (un-
published data), whereas under such conditions
P120 is phosphorylated at a tyrosine residue
(27).
A striking coincidence in our data is that the
one A-MuLV-induced tumor that is rejected by
syngeneic mice is L1-2 (28), the only A-MuLV-
induced tumor that lacks a detectable band of
biosynthetically labeled P50. L1-2 cells appear
to have some P50 by immunofluorescence anal-
ysis, but the level must be quite low. Other A-
MuLV-induced lymphoid cell lines from C57L
mice have P50 and are lethal to syngeneic hosts
(Rotter, Rosenberg, and Baltimore, unpublished
data); thus, the uniqueness of L1-2 lies in the
properties of the cell line and not in the genetics
of C57L animals. How a low level of P50 might
potentiate tumor rejection is not clear, and fur-
ther investigation of this coincidence will be
required before we can know if the low P50
content of L1-2 causes its rejection by C57L
animals.
Whatever the role of P50 in tumor rejection,
it is striking that mice often respond to this
protein even in a syngeneic immunization. Pre-
sumably the concentration of the protein in the
A-MuLV-induced cell lines is high enough to
break tolerance. Were it not for the widespread
occurrence of P50, it might be considered a
"tumor antigen" because of the selective in-
crease in antibody to the protein in tumor-bear-
ing or rejecting animals.
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Risser et al. described an A-MuLV-related
antigen that had a normal BALB/c counterpart
in hematopoietic tissues of uninfected mice (16,
17). We previously compared their data with
data from our laboratory on the one known A-
MuLV-encoded protein, P120, and its congeners
and questioned whether their antigen is encoded
by the A-MuLV genome (27). We now believe
that P50 is probably the protein responsible for
the antigenicity they described. P50 is found on
the cell types they found to be positive and is,
by cell surface analysis, a B-lymphocyte differ-
entiation antigen readily apparent in BALB/c
mice (Coffman and Weissman, in preparation).
Because of the approximate coincidence of
size, we have investigated whether P50 might be
the same antigen described by DeLeo et al. (4,
5) as a 53,000-molecular-weight protein elevated
in chemically induced BALB/c tumor cells, or
whether it might be related to the 54,000 to
56,000-molecular-weight protein that is elevated
in simian virus 40-transformed cells and binds to
the simian virus 40 T-antigen, or both (2, 8, 10-
12, 25). Preliminary experiments have shown
that the three proteins are closely related and
probably identical (Rotter and Baltimore, un-
published data). Thus, P50 is elevated in a va-
riety of tumor cells and may be involved in the
malignant state of tumor cells induced by a
variety of carcinogenic stimuli.
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